Tyra Biosciences EPS TYRA
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$2.40
- Latest quarter, Q2 FY26
- −$0.69
- Fiscal year 2025
- −$2.01
Tyra Biosciences' earnings per share was −$2.40 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.69.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.01 | n/a |
| FY2024 | −$1.51 | n/a |
| FY2023 | −$1.61 | n/a |
| FY2022 | −$1.33 | n/a |
| FY2021 | −$5.48 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.69 | n/a | −$2.40 | |
| Q1 FY26 | −$0.64 | n/a | −$2.18 | |
| Q4 FY25 | −$0.57 | n/a | −$2.01 | |
| Q3 FY25 | −$0.50 | n/a | −$1.87 | |
| Q2 FY25 | −$0.47 | n/a | −$1.78 | |
| Q1 FY25 | −$0.47 | n/a | −$1.63 | |
| Q4 FY24 | −$0.43 | n/a | −$1.51 | |
| Q3 FY24 | −$0.41 | n/a | −$1.61 | |
| Q2 FY24 | −$0.32 | n/a | −$1.69 | |
| Q1 FY24 | −$0.35 | n/a | −$1.68 | |
| Q4 FY23 | −$0.53 | n/a | −$1.61 | |
| Q3 FY23 | −$0.49 | n/a | −$1.39 |
Against its peers
Companies in Drug Manufacturers - General nearest Tyra Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TYRATyra Biosciences | −$2.40 | |
| OMEROmeros | $1.52 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| ABUSArbutus Biopharma | $0.78 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| Peer median | $2.07 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Tyra Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.